Analyst Terence Flynn from Morgan Stanley maintained a Buy rating on Intellia Therapeutics (NTLA – Research Report) and keeping the price ...
the company worked with Vertex Pharmaceuticals and CRISPR Therapeutics on this first-of-its-kind CRISPR/Cas9 genome-edited cell therapy. In total, MaxCyte has signed 29 SPL agreements with cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback